Selecta Biosciences Inc (NASDAQ:SELB)’s stock price shot up 5.8% during trading on Tuesday . The stock traded as high as $1.69 and last traded at $1.65, 709,857 shares traded hands during trading. An increase of 341% from the average session volume of 160,975 shares. The stock had previously closed at $1.56.
Several research firms have recently commented on SELB. Needham & Company LLC reiterated a “buy” rating and set a $9.00 price objective on shares of Selecta Biosciences in a research note on Friday, November 8th. Stifel Nicolaus reiterated a “buy” rating and set a $6.00 price objective on shares of Selecta Biosciences in a research note on Friday, November 8th. Finally, Zacks Investment Research downgraded shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, October 10th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $6.80.
The company has a market capitalization of $79.53 million, a price-to-earnings ratio of -0.57 and a beta of 1.17. The business’s 50-day moving average is $1.49 and its 200-day moving average is $1.75.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC purchased a new position in Selecta Biosciences in the second quarter valued at $31,000. A.R.T. Advisors LLC purchased a new position in Selecta Biosciences in the second quarter valued at $40,000. Morgan Stanley increased its holdings in Selecta Biosciences by 582.4% in the second quarter. Morgan Stanley now owns 63,784 shares of the company’s stock valued at $114,000 after buying an additional 54,437 shares in the last quarter. Jane Street Group LLC purchased a new position in Selecta Biosciences in the second quarter valued at $195,000. Finally, Paloma Partners Management Co purchased a new position in Selecta Biosciences in the second quarter valued at $275,000. Institutional investors own 39.55% of the company’s stock.
Selecta Biosciences Company Profile (NASDAQ:SELB)
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Recommended Story: What is the role of the G-20?
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.